发明名称 USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES
摘要 This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a pharmaceutical composition for the treatment of immune disease or allergy which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of immune disease or allergy in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.
申请公布号 KR20130040787(A) 申请公布日期 2013.04.24
申请号 KR20127024115 申请日期 2011.02.22
申请人 RAQUALIA PHARMA INC. 发明人 KANAZAWA KIYOSHI;NONOMURA KAZUHIKO;OKUMURA TAKAKO;KOIZUMI SHINICHI
分类号 A61K31/38;A61K31/437;A61K31/44;A61K31/4412 主分类号 A61K31/38
代理机构 代理人
主权项
地址